Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

92 Applying Pharmacogenomics in Therapeutics
34. Jones G, Willett P. Docking small-molecule ligands into active sites. Curr Opin
Biotechnol 1995;6:652–6.
35. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: Applications
to targets and beyond. Br J Pharmacol 2007;152:21–37.
36. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating
protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197–206.
37. Poroikov V, Filimonov D, Lagunin A, Gloriozova T, Zakharov A. PASS:
Identification of probable targets and mechanisms of toxicity. SAR QSAR Environ Res
2007;18:101–10.
38. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target?
Drug Discov Today 2011;17(Suppl):S24–30.
39. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing:
Relevance in medical practice: Why drugs work in some patients but not in others.
Cleve Clin J Med 2011;78:243–57.
40. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997;10:203–22.
41. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE,
Stella GM, et al. Replacement of normal with mutant alleles in the genome of normal
human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A
2008;105:20864–9.
42. Kore PP, Mutha MM, Antre RV, Oswal RJ, Kshirsagar SS. Computer-aided drug
design: An innovative tool for modeling. Open J Med Chem 2012;2:139–48.
43. Nisius B, Sha F, Gohlke H. Structure-based computational analysis of protein binding
sites for function and druggability prediction. J Biotechnol 2012;159:123–34.
44. DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: A race or imitation?
Nat Rev Drug Discov 2011;10:23–7.
45. Ruan ZX, Huangfu DS, Xu XJ, Sun PH, Chen WM. 3D-QSAR and molecular
docking for the discovery of ketolide derivatives. Expert Opin Drug Discov 2013;
8:427–44.
46. Ishikawa T, Sakurai A, Kanamori Y, Nagakura M, Hirano H, Takarada Y, Yamada K,
Fukushima K, Kitajima M. High-speed screening of human ATP-binding cassette
transporter function and genetic polymorphisms: New strategies in pharmacogenomics.
Methods Enzymol 2005;400:485–510.
47. Powers R. Advances in nuclear magnetic resonance for drug discovery. Expert
Opin Drug Discov 2009;4:1077–98.
48. Jason-Moller L, Murphy M, Bruno J. Overview of Biacore systems and their applications.
Curr Protoc Protein Sci 2006;Chapter 19:Unit 19.3.
49. Leon-Cachon RB, Ascacio-Martinez JA, Barrera-Saldana HA. Individual response
to drug therapy: Bases and study approaches. Rev Invest Clin 2012;64:364–76.
50. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery.
Br J Pharmacol 2011;162:1239–49.
51. Kinnings SL, Xie L, Fung KH, Jackson RM, Bourne PE. The Mycobacterium
tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol
2010;6:e1000976.
52. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, et al.
ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD
mouse models. Science 2012;335:1503–6.
53. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-ofillness
model. J Am Pharm Assoc (Wash) 2001;41:192–9.
54. Ono C, Kikkawa H, Suzuki A, Suzuki M, Yamamoto Y, Ichikawa K, Fukae M,
Ieiri I. Clinical impact of genetic variants of drug transporters in different ethnic
groups within and across regions. Pharmacogenomics 2013;14:1745–64.